

# COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels, 05-IX-2005 C(2005)3436

**NOT FOR PUBLICATION** 

## **COMMISSION DECISION**

of 05-IX-2005

amending the marketing authorisation for "Ventavis - Iloprost", a medicinal product for human use, granted by Decision C(2003)3348

ONLY THE GERMAN TEXT IS AUTHENTIC



#### **COMMISSION DECISION**

#### of 05-IX-2005

# amending the marketing authorisation for "Ventavis - Iloprost", a medicinal product for human use, granted by Decision C(2003)3348

(Text with EEA relevance)

#### THE COMMISSION OF THE EUROPEAN COMMUNITIES.

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products<sup>1</sup>.

Having regard to Commission Regulation (EC) No 1085/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products falling within the scope of Council Regulation (EEC) No 2309/93<sup>2</sup>, and in particular the first subparagraph of Article 6(10) thereof,

Having regard to the application submitted by Schering AG on 14 January 2005 under Article 6(1) of Commission Regulation (EC) No 1085/2003,

Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use<sup>3</sup>, and in particular Article 61(3) thereof,

Having regard to the opinion of the European Medicines Agency, formulated by the Committee for Medicinal Products for Human Use on 27 July 2005,

#### Whereas:

(1) An examination of the major variation type II to the terms of the marketing authorisation for the medicinal product "Ventavis - Iloprost", which is entered in the Community Register of Medicinal Products under No(s) EU/1/03/255/001-003 and the placing on the market of which was authorised by Decision

<sup>&</sup>lt;sup>3</sup> OJ L 311, 28.11.2001, p. 67. Directive as last amended by [Directive 2004/27/EC (OJ L 136, 30.4.2004, p. 34).]



FN

<sup>&</sup>lt;sup>1</sup> OJ L 214, 24.8.1993, p. 1. Regulation as last amended by [Regulation (EC) No 1647/2003 (OJ L 245, 29.9.2003, p. 19)].

<sup>&</sup>lt;sup>2</sup> OJ L 159, 27.6.2003, p. 24.

C(2003)3348 of 16 September 2003, has shown that the product remains in compliance with the requirements set out in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use<sup>4</sup>.

- (2) It is therefore appropriate to accept the application in respect of a major variation to the terms of the marketing authorisation and to amend Decision C(2003)3348 accordingly.
- Ouring the same period, Schering AG submitted, under Article 61(3) of Directive 2001/83/EC, a notification(s) for changes to an aspect of the labelling or the package leaflet. The competent authority did not oppose the proposed change within the 90-day time-limit.
- (4) The marketing authorisation should be updated, and Decision C(2003)3348 amended accordingly.
- (5) For the sake of clarity and transparency, it is advisable, following the amendment of part or parts of the Annexes, to provide for a consolidated version thereof. The Annexes to Decision C (2003)3348 should therefore be replaced,

#### HAS ADOPTED THIS DECISION:

### Article 1

Decision C(2003)3348 is amended as follows:

1) The list of notifications for changes to an aspect of the labelling or the package leaflet, accepted between 19 November 2004 and 27 July 2005, is added to the updated marketing authorisation;

Application number Annex (EU numbers affected)

EMEA/H/C/000474/N/0004 IIIAB (EU/1/03/255/001-003)

- 2) Annex I is replaced by the text set out in Annex I to this Decision;
- 3) Annex III is replaced by the text set out in Annex III to this Decision.

<sup>&</sup>lt;sup>4</sup> OJ L 311, 28.11.2001, p. 67. Directive as last amended by [Directive 2004/27/EC (OJ L 136, 30.4.2004, p.34)].



# Article 2

This Decision is addressed to Schering AG, Müllerstrasse 170-178, D - 13342 Berlin, Deutschland.

Done at Brussels, 05-IX-2005

For the Commission
Günter VERHEUGEN
Member of the Commission

